Pharmacological Inhibition of Voltage-gated Ca(2+) Channels for Chronic Pain Relief
Related Experiment Video
Updated: May 4, 2026

Electrophysiological Methods to Assess Peripheral Pain Block in an Anesthetized Rat
Published on: November 21, 2025
1F. M. Kirby Neurobiology Center, Children's Hospital Boston, Boston MA 02115 USA; ; Department of Neurobiology, Harvard Medical School, Boston MA 02115 USA.
Abstract:
Chronic pain is a major therapeutic problem as the current treatment options are unsatisfactory with low efficacy and deleterious side effects. Voltage-gated Ca2+ channels (VGCCs), which are multi-complex proteins consisting of α1, β, γ, and α2δ subunits, play an important role in pain signaling. These channels are involved in neurogenic inflammation, excitability, and neurotransmitter release in nociceptors. It has been previously shown that N-type VGCCs (Cav2.2) are a major pain target. U.S. FDA approval of three Cav2.2 antagonists, gabapentin, pregabalin, and ziconotide, for chronic pain underlies the importance of this channel subtype. Also, there has been increasing evidence that L-type (Cav1.2) or T-type (Cav3.2) VGCCs may be involved in pain signaling and chronic pain. In order to develop novel pain therapeutics and to understand the role of VGCC subtypes, discovering subtype selective VGCC inhibitors or methods that selectively target the inhibitor into nociceptors would be essential. This review describes the various VGCC subtype inhibitors and the potential of utilizing VGCC subtypes as targets of chronic pain. Development of VGCC subtype inhibitors and targeting them into nociceptors will contribute to a better understanding of the roles of VGCC subtypes in pain at a spinal level as well as development of a novel class of analgesics for chronic pain.
Insights
Voltage-gated calcium channels (VGCCs) are crucial in pain signaling. Targeting specific VGCC subtypes offers a promising avenue for developing novel, effective chronic pain therapeutics with fewer side effects.
Area of Science:
- Neuroscience
- Pharmacology
- Pain Research
Background:
- Chronic pain presents a significant therapeutic challenge due to current treatment limitations, including low efficacy and adverse effects.
- Voltage-gated calcium channels (VGCCs), composed of various subunits, are integral to pain signaling pathways, influencing neurogenic inflammation, neuronal excitability, and neurotransmitter release in nociceptors.
- N-type VGCCs (Cav2.2) are established pain targets, evidenced by FDA-approved drugs like gabapentin, pregabalin, and ziconotide.
Purpose of the Study:
- To review existing VGCC subtype inhibitors and explore their potential as targets for novel chronic pain therapeutics.
- To highlight the emerging roles of L-type (Cav1.2) and T-type (Cav3.2) VGCCs in pain signaling.
- To emphasize the necessity of developing subtype-selective VGCC inhibitors or targeted delivery methods for nociceptors.
Main Methods:
- Literature review of studies investigating VGCCs in pain signaling.
- Analysis of current and potential therapeutic strategies targeting VGCC subtypes.
- Discussion of the role of different VGCC subtypes (Cav2.2, Cav1.2, Cav3.2) in chronic pain mechanisms.
Main Results:
- N-type VGCCs (Cav2.2) are validated targets for chronic pain management.
- Evidence suggests L-type (Cav1.2) and T-type (Cav3.2) VGCCs also contribute to pain signaling.
- Subtype-selective inhibition and targeted delivery are key for advancing VGCC-based pain therapies.
Conclusions:
- Developing subtype-selective VGCC inhibitors is essential for advancing chronic pain treatment.
- Targeting specific VGCCs in nociceptors can lead to a new class of analgesics.
- Further research into VGCC subtypes will improve understanding of spinal pain mechanisms and therapeutic development.
Related Concept Videos
Analgesia and Pain Management
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Pain
Non-gated Ion Channels
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
Voltage-gated Ion Channels
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
Nociception

